This product is ineffective for patients with asthma or chronic obstructive pulmonary disease and may even cause danger. Literature reports that after using this product, patients with mild or moderate asthma can cause bronchospasm, and patients who cause bronchospasm should stop taking the drug and inform their attending doctors. When patients with respiratory diseases take zanamivir, they should have inhaled quick-acting bronchodilators around them. Other adverse reactions of taking this medicine include: headache, diarrhea, nausea, vomiting, dizziness and so on. The incidence is less than 2%, and most of them are mild reactions.

Animal experiments show that zanamivir is not carcinogenic, teratogenic and mutagenic, and has no reproductive toxicity. Zanamivir can pass through the placental barrier in animal experiments, and the fetal blood concentration is significantly lower than that of the mother. There is a lack of sufficient and effective research results to confirm the pharmacokinetics of pregnant women, so the impact on the fetus should be weighed when using it. Zanamivir was detected in the milk of lactating rats. However, the existence of drugs in human milk is uncertain, and nursing women should be cautious in using this drug. The adverse reactions of this drug to the elderly and children under 12 years old are uncertain.

There is no obvious drug interaction in vitro, and this product does not affect liver microsomal enzymes, nor is it the substrate of P450 enzymes.